

Applicants: D. E. Yelton and M. J. Rosok  
Serial No.: 08/905,293  
Filed: August 1, 1997  
Page 2

26. (Amended) The method of claim [30] 25, wherein the structurally altered immunoglobulin in the composition is labeled so as to directly or indirectly produce a detectable signal with a compound selected from the group consisting of a radiolabel, an enzyme, a chromophore, a chemiluminescer, and a fluorescer.

a<sup>2</sup>  
27. (Amended) The method of claim [24] 25, wherein the Ig fusion protein in the composition is labeled so as to directly or indirectly produce a detectable signal with a compound selected from the group consisting of a radiolabel, an enzyme, a chromophore, a chemiluminescer, and a fluorescer.

28. (Amended) The method of claim 2 [or 5], wherein the antibody is conjugated to a cytotoxic agent.

29. (Amended) The method of claim 1 or 5, wherein the immunoglobulin is conjugated to a cytotoxic agent.

a<sup>3</sup>  
31. (Amended) The method of claim 28[, 29, or 31], wherein the cytotoxic agent is selected from the group consisting of antimetabolites, alkylating agents, anthracyclines, antibiotics, anti-mitotic agents, and chemotherapeutic agents.

#### REMARKS

The amendments to the specification are editorial and do not introduce new matter. Applicants respectfully request entry of these amendments.

When the Examiner takes the application up for the first Office Action, consideration of the Amendments and remarks presented herein is respectfully requested.